Guardant Health had a busy third quarter of 2021, investing in new trials to help it grow toward profitability.
In October, the company initiated the Observation of ResiduAl Cancer with Liquid biopsy Evaluation (ORACLE) study. The 1,000-patient study, which will improve upon its prior COBRA, ACT-3 and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?